Skip to content
value.today

Pfizer Inc.: financial analysis

Ratios worked out from 10 fiscal years of Pfizer Inc.'s statements, compared with 102 companies in Pharmaceutical.

Return on equity, 2025
8.9%
Pharmaceutical: -0.9%
Revenue growth, 3 years a year, 2025
-14.8%
Pharmaceutical: 2.5%
Debt to equity, 2025
0.71×
Pharmaceutical: 0.66×
Free cash flow margin, 2025
14.5%
Pharmaceutical: 6.0%

Pfizer Inc. scorecard#

Passes 11 of the 21 checks that could be worked out: strongest in financial health (3 of 3), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation3 of 6
    • ✗P/E below its peers' median42.3×P/E 42.3× against Pharmaceutical's median of 39.4×.
    • ✓Price to book below its peers' median2.0×Price to book 2.0× against Pharmaceutical's median of 3.2×.
    • ✓Price to sales below its peers' median2.7×Price to sales 2.7× against Pharmaceutical's median of 3.5×.
    • ✓Free cash flow yield above 5%5.3%Free cash flow is 5.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yield2.4%Earnings yield 2.4% against the 10-year Treasury's 5.15% on 2026-11-13.
    • ✗The price assumes slower growth than the last three years'13.2%The price assumes 13.2% a year for ten years; revenue grew -14.8% a year over the last three.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-1.6%Revenue down 1.6% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-14.8%-14.8% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-14.8%-14.8% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year1.36 vs 1.41Diluted EPS 1.36 in fiscal 2025 against 1.41 the year before (report's currency).
    • ✗Net income higher than five years earlier$7.8 B$7.8 B in fiscal 2025 against $9.2 B in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability2 of 3
    • ✓Profitable in the newest year$7.8 BNet income $7.8 B in fiscal 2025.
    • ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%8.9%8.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 3
    • ✓Short-term assets cover short-term liabilities1.2×Current ratio 1.16 at the end of fiscal 2025.
    • ✓Debt below equity0.7×Debt to equity 0.71 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns3 of 3
    • ✓Pays a dividendYesPaid dividends in fiscal 2025.
    • ✓Dividend per share raised five years in a row5 of 5Dividend per share raised in 5 of the five years to fiscal 2025.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.2%Diluted shares up 0.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • Free cash flow has been positive 17 years in a row.
  • The dividend per share has been raised 15 years in a row.

Worth a look

  • Revenue fell 1.6% against the year before.
  • Goodwill and intangibles ($125.0 billion) exceed shareholders' equity ($86.5 billion).

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

5of 9
  • Made a profityes
  • Operations brought in cashyes
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsno
  • Current ratio roseno
  • No new shares issuedno
  • Gross margin roseyes
  • Asset turnover roseyes

Where the return on equity comes from

The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.

Net margin12.4%Asset turnover0.30×Assets to equity2.39×Return on equity8.9%

Profitability#

Pfizer Inc.: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Gross margin74.3%71.9%58.1%66.1%62.1%53.3%83%
Net margin12.4%12.6%3.6%31.0%27.0%-1.5%80%
Return on equity8.9%9.1%2.3%36.3%31.3%-0.9%65%
Return on assets3.7%3.7%1.0%16.6%13.1%-1.3%64%

Growth#

Pfizer Inc.: growth by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Revenue growth-1.7%6.8%-41.1%24.5%95.2%7.3%19%
Revenue growth, 3 years a year-14.8%-7.8%12.7%35.2%25.8%2.5%11%
Revenue growth, 5 years a year8.5%9.2%7.8%14.0%9.0%6.0%62%
Net income growth-3.2%279.0%-93.3%42.7%140.0%14.3%27%
Earnings per share growth-3.6%281.1%-93.2%42.1%136.2%12.4%29%

Financial strength#

Pfizer Inc.: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Debt to equity0.71×0.65×0.69×0.34×0.47×0.66×49%
Net debt$60.5 B$56.4 B$58.7 B$32.5 B$34.3 B$188 M0%
Current ratio1.16×1.17×0.91×1.22×1.40×1.98×32%
Equity share of assets41.5%41.3%39.3%48.5%42.5%47.3%43%

Cash#

Pfizer Inc.: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Free cash flow$9.1 B$9.8 B$4.8 B$26.0 B$29.9 B$8 M94%
Free cash flow margin14.5%15.5%8.1%25.7%36.7%6.0%74%
Cash conversion150.6%158.7%410.6%93.3%148.2%136.7%58%
Capital spending share of revenue4.2%4.6%6.6%3.2%3.3%2.6%—

Shareholder returns#

Pfizer Inc.: shareholder returns by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Change in share count0.2%-0.2%-0.4%0.4%1.4%1.8%71%

Efficiency#

Pfizer Inc.: efficiency by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Asset turnover0.30×0.29×0.28×0.53×0.48×0.55×10%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Net income growth
Net income against the year before. Only when both years were profitable.
Earnings per share growth
Diluted earnings per share against the year before. Only when both were positive.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Pfizer Inc.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 102 companies in Pharmaceutical that Pfizer Inc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Pfizer Inc.